The IMS is proud to present the new “Global Leadership Opportunity” or GLO to empower the next generation of myeloma leadership. Get ready to GLO with IMS and apply today: https://t.co/4msWWv52AU
The IMS is proud to present the new “Global Leadership Opportunity” or GLO to empower the next generation of myeloma leadership. Get ready to GLO with IMS and apply today: https://t.co/4msWWv52AU
@mehak_trehan@RahulDoc2@nikhil91sjmc Current Status and Future Perspectives of CXCR4-based Radio-theranostics in Human Cancers: A Review. Clin Nucl Med. 2026 Jan 1;51(1):e72-e83. doi: 10.1097/RLU.0000000000005828. Epub 2025 Dec 3. PMID: 41365512.
@mehak_trehan@RahulDoc2@nikhil91sjmc 68 Ga-Pentixafor PET/CT-Based Response Evaluation and its Prognostic Value in Multiple Myeloma: Comparison With IMWG and 18 F-FDG-Based Response. Clin Nucl Med. 2025 Jun 1;50(6):e331-e339. doi: 10.1097/RLU.0000000000005731.
@mehak_trehan@RahulDoc2@nikhil91sjmc Imaging CXCR4 receptors expression for staging multiple myeloma by using 68Ga-Pentixafor PET/CT: comparison with 18F-FDG PET/CT. Br J Radiol. 2022 Aug 1;95(1136):20211272. doi: 10.1259/bjr.20211272.
Publications from PGI Chd: Imaging CXCR4 receptors expression for staging multiple myeloma by using 68Ga-Pentixafor PET/CT: comparison with 18F-FDG PET/CT. Br J Radiol. 2022 Aug 1;95(1136):20211272. doi: 10.1259/bjr.20211272.
@UdayYanamandra@DrNikitaMehra@IndMyAcGp Excellent work ! Being a Gujarati I get ton of calls from patients who wants to learn and understand in Gujarati; this is fantastic 👏👏